My Queue

There are no Videos in your queue.

Click on the Add to next to any video to save to your queue.

There are no Articles in your queue.

Click on the Add to next to any article to save to your queue.

There are no Podcasts in your queue.

Click on the Add to next to any podcast episode to save to your queue.

You're not following any authors.

Click the Follow button on any author page to keep up with the latest content from your favorite authors.


Theranos May Have Run Blood Tests Despite Quality Issues

Theranos May Have Run Blood Tests Despite Quality Issues
Image credit: Theranos | Facebook
Theranos founder and CEO, Elizabeth Holmes.
2 min read
This story originally appeared on Fortune Magazine

A federal inspection report may offer new evidence that Theranos ran blood tests despite questionable results.

The Centers for Medicare and Medicaid Services (CMS) report, which the Wall Street Journal learned about despite not yet being released to the public, found that Theranos continued to run the tests on patients despite erratic quality control results. Eighty one patients in a six-month period received hematology results that were not adequately controlled for quality.

The unreleased report follows a letter that the CMS sent to Theranos in January. That letter was short on specific issues with the startup’s methods, but it cited five major infractions that “pose immediate jeopardy to patient health and safety,” according to the Journal.

The blood test that Theranos continued to perform despite quality issues measured the ability of blood to clot -- an important test that doctors use to adjust patients’ dosages of blood thinners.

In a statement on the company’s website, Theranos’ newly hired California lab director Kingshuk Das said that the problems identified in the report are no longer present: “We have conducted assessments to identify any patients affected or having the potential to be affected by the issues identified by CMS, and we have no reason to believe that these issues have affected patients’ health.”

Theranos -- the Silicon Valley Unicorn that’s been valued at around $9 billion -- has fallen under scrutiny after a Journal investigation in October found that the startup was using its own machines for only a small fraction of blood tests.

Fortune has reached out to Theranos for further comment and will update this story if the company responds.

More from Entrepreneur

Corene Summers helps clients advancing their health, careers and lives overall through reducing stress, tension and optimizing sleep.
Jumpstart Your Business. Entrepreneur Insider is your all-access pass to the skills, experts, and network you need to get your business off the ground—or take it to the next level.
Starting, buying, or growing your small business shouldn’t be hard. Guidant Financial works to make financing easy for current and aspiring small business owners by providing custom funding solutions, financing education, and more.

Latest on Entrepreneur